Sichenzia Ross Ference Kesner LLP Congratulates TapImmune Inc. on NASDAQ Uplisting
New York, NY – November 3, 2016 – Sichenzia Ross Ference Kesner LLP announced today that the Firm has represented TapImmune Inc. (NASDAQ: TPIV), in the Company’s uplisting to the NASDAQ Capital Market. The Sichenzia Ross Ference Kesner LLP team was led by founding Partner Gregory Sichenzia and Associate Jay Yamamoto. The uplisting is effective for trading on November 8, 2016 and TapImmune’s common stock will trade under its existing stock symbol “TPIV.”
“We congratulate TapImmune on this milestone, one we believe will support the Company’s strategic capital markets objectives as it continues to develop its peptide and gene based immunotherapeutics for the treatment of cancer,” said Gregory Sichenzia, partner of Sichenzia Ross Ference Kesner LLP.
Visit SRF's LinkedIn page